Equities

Gossamer Bio Inc

Gossamer Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.05
  • Today's Change0.090 / 9.40%
  • Shares traded2.39m
  • 1 Year change+18.20%
  • Beta1.9577
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments296256325
Total Receivables, Net------
Total Inventory------
Prepaid expenses106.206.50
Other current assets, total--00.06
Total current assets307262332
Property, plant & equipment, net4.789.8911
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.620.681.08
Total assets312272344
LIABILITIES
Accounts payable5.531.463.24
Accrued expenses343637
Notes payable/short-term debt000
Current portion long-term debt/capital leases1212--
Other current liabilities, total------
Total current liabilities524940
Total long term debt197208179
Total debt209219179
Deferred income tax------
Minority interest------
Other liabilities, total0.143.453.22
Total liabilities249260222
SHAREHOLDERS EQUITY
Common stock0.020.010.01
Additional paid-in capital1,2751,045933
Retained earnings (accumulated deficit)(1212)(1032)(812)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.35)(0.57)0.05
Total equity6312121
Total liabilities & shareholders' equity312272344
Total common shares outstanding2259476
Treasury shares - common primary issue00.060.72
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.